Ahold Delhaize reported a solid set of 2Q25 results, with comparable sales growth of 3.4% in the US (css: +3.1%) and +4.9% in the EU (css: +3.8%) exceeding expectations. While group margins contracted by 20bps to 4.0%, this was well anticipated on the back of ongoing price investments in the US and the dilutive impact from the consolidation of Profi in the EU. As such, the underlying group EBIT of € 917m came in slightly ahead of expectations (css: € 908m, css: € 905m). Following the solid 2Q25,...
ABN AMRO: Better bottom line, mixed underlying, strong capital, SBB €250m. Ahold Delhaize: 2Q25 profitability beat thanks to insurance results. Coca-Cola Europacific Partners PLC: Fizzing along nicely. Kinepolis: July 2025 box office in US/Canada and France down, on strong comps. Vonovia: Good results, 5.6% guidance increase. UCB: Evenity continues to surprise to the upside. Zabka: Another miss on Adj. Net Income in 2Q25
Rdos. 2T'25 vs 2T'24: Ventas: 23.092 M euros (+3,3% vs +2,8% BS(e) y +2,7% consenso); EBIT: 917,0 M euros (-1,7% vs -2,9% BS(e) y -2,7% consenso); BDI: 548,0 M euros (+9,8% vs +14,4% BS(e) y +14,2% consenso). Rdos. 1S'25 vs 1S'24: Ventas: 46.368 M euros (+5,2% vs +4,9% BS(e) y +4,9% consenso); EBIT: 1.807 M euros (+0,7% vs +0,1% BS(e) y +0,2% consenso);
Alfen: Preview - muddling through? Belgian telcos: Competition Authority investigation on Proximus/Orange Belgium MoU. Brunel International: 2Q25 below, 3Q25 outlook cut, cost savings protect FY25 estimates. Euronext: Another record set of results. Fugro: Sharper V-shape? GBL: Weak NAV performance, as expected. KBC Ancora: Cooperative CERA increasing its stake to 51.24%, using excess cash. UCB: Renewed US threats to cut drug prices. Umicore: 1H25 and guide broadly in-line, new S...
We upgrade our 2026 Bimzelx sales to be €0.9bn higher than consensus with conservative assumptions & and are now 11% above consensus on 2026 group sales & 19% on EBITDA. We upgrade our already above-consensus ‘27 EBITDA by 5%. Using our proprietary product-by-product Contribution Analysis, we show that the gross margin is highly sensitive to Bimzelx growth. We analyse the galvokimig data, which looks very strong Vs Dupi. Whilst UCB pipeline readouts & Moonlake risk will dominate specialists’ tho...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.